Description: Tryp Therapeutics Inc., a clinical stage pharmaceutical company, focuses on developing compounds with known activity and/or safety profiles for the treatment of rare or orphan diseases and other diseases. The company's lead development program is psilocybin-for-neuropsychiatry (PFN), which is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. Its PFN program candidates include TRP-8802 for fibromyalgia, hyperphagia in prader-willi syndrome, and other therapies; and TRP-1001, an oral formulation of razoxane evaluating for the treatment of soft tissue sarcoma. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. The company was founded in 2019 and is headquartered in Kelowna, Canada.
Home Page: www.tryptherapeutics.com
1665 Ellis Street
Kelowna,
BC
V1Y 2B3
Canada
Phone:
833 811 8797
Officers
| Name | Title |
|---|---|
| Dr. James P. Gilligan MSIB, Ph.D. | Interim CEO, Pres & Chief Scientific Officer |
| Dr. James S. Kuo M.B.A., M.D. | Co-Founder & Director |
| Mr. Jim O'Neill | Chief Financial Officer |
| Mr. Thomas D'Orazio B.Sc., M.B.A. | Chief Operating Officer |
| Mr. Sidney Taubenfeld R.Ph | Chief Operating Officer |
| Ms. Joy Willis | Director of Investor Relations |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.499 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | August |
| Full Time Employees: | 0 |